Ultragenyx cuts staff after another study fails
Biotech company Ultragenyx announced it is cutting staff following the failure of another clinical study.
Company announces workforce reductions
Ultragenyx has decided to reduce its number of employees after recent research efforts did not meet expectations. The company cited the outcome of a specific study as the reason for these internal changes. This decision marks another setback for the firm in its ongoing development pipeline.
Industry context and competition
Other major pharmaceutical firms like Novo Nordisk are currently adjusting their financial guidance based on drug performance. Eli Lilly faces growing competition with its own oral obesity medicine entering the market. These industry shifts highlight the competitive landscape that Ultragenyx now navigates while managing its internal restructuring.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.